KIR/HLA genotypes confer susceptibility and progression in patients with autoimmune hepatitis.
AIH
HLA
Killer cell immunoglobulin-like receptors
NK cell
outcome
Journal
JHEP reports : innovation in hepatology
ISSN: 2589-5559
Titre abrégé: JHEP Rep
Pays: Netherlands
ID NLM: 101761237
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
received:
09
07
2019
revised:
12
09
2019
accepted:
19
09
2019
entrez:
11
2
2020
pubmed:
11
2
2020
medline:
11
2
2020
Statut:
epublish
Résumé
Natural killer (NK) cells are key participants in the innate immune response. Killer cell immunoglobulin-like receptors (KIRs) are involved in the activation and inhibition of NK cells through the recognition of human leukocyte antigen (HLA) class I molecules. We investigated the impact of KIR/HLA combinations on susceptibility and long-term clinical outcome in Japanese patients with type 1 autoimmune hepatitis (AIH). A total of 154 cases of AIH were recruited at Shinshu University Hospital between 1974 and 2018. KIR genes and HLA class I and II alleles were genotyped in all patients along with 201 healthy individuals. Associations between KIR/HLA pairs and clinical outcomes (liver decompensation and liver-related death) were evaluated using the Cox proportional hazards model with stepwise method. After a median follow-up period of 11.1 years, 12% of patients experienced liver decompensation and 8% died from liver disease. KIR3DL1/HLA-B Bw4-80Ile ( This study revealed the impact of specific KIR/HLA pairs in AIH susceptibility and progression in Japanese patients. KIR3DL1/HLA-B Bw4-negative patients with AIH and cirrhosis at diagnosis are at high risk of adverse outcomes and require careful surveillance. Autoimmune hepatitis (AIH) is a disease of the liver that can present in acute or chronic hepatitis. We examined whether KIR/HLA pairs were associated with AIH susceptibility or disease progression. KIR3DL1/HLA-B Bw4 was a novel KIR/HLA pair related to a favorable clinical outcome, while cirrhosis at the initial diagnosis was a risk factor for poor prognosis. Thus, frequent and careful surveillance is advised for KIR3DL1/HLA-B Bw4-negative patients with AIH and cirrhosis.
Identifiants
pubmed: 32039386
doi: 10.1016/j.jhepr.2019.09.003
pii: S2589-5559(19)30108-9
pmc: PMC7005656
doi:
Types de publication
Journal Article
Langues
eng
Pagination
353-360Informations de copyright
© 2019 The Authors.
Références
Autoimmun Rev. 2018 Sep;17(9):854-865
pubmed: 30005861
Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):12000-4
pubmed: 8265660
J Hepatol. 2015 Oct;63(4):971-1004
pubmed: 26341719
Hepatology. 1997 Feb;25(2):317-23
pubmed: 9021941
Hepatol Commun. 2018 Feb 26;2(4):421-436
pubmed: 29619420
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Clin Gastroenterol Hepatol. 2019 Apr;17(5):940-947.e2
pubmed: 30291909
Hepatology. 2015 Nov;62(5):1524-35
pubmed: 26178791
Nat Immunol. 2008 May;9(5):503-10
pubmed: 18425107
Oncotarget. 2018 Apr 13;9(28):19650-19661
pubmed: 29731972
Nat Genet. 2002 Aug;31(4):429-34
pubmed: 12134147
J Hepatol. 2017 Sep;67(3):462-470
pubmed: 28412292
Hepatology. 2001 Mar;33(3):544-53
pubmed: 11230733
Clin Immunol. 2018 Mar;188:31-37
pubmed: 29233784
Blood. 2008 Jul 15;112(2):435-43
pubmed: 18385451
Hepatology. 2013 Oct;58(4):1392-400
pubmed: 23686586
Hepatology. 2012 Aug;56(2):668-76
pubmed: 22334246
PLoS One. 2014 Jun 23;9(6):e100565
pubmed: 24956105
J Exp Med. 2006 Mar 20;203(3):633-45
pubmed: 16533882
Dig Dis Sci. 2015 Oct;60(10):2873-80
pubmed: 25999245
Hum Immunol. 1994 Oct;41(2):146-50
pubmed: 7860360
Eur J Immunol. 2004 Jun;34(6):1673-9
pubmed: 15162437
Tissue Antigens. 2000 Dec;56(6):522-9
pubmed: 11169242
Gastroenterology. 1997 Jun;112(6):2028-35
pubmed: 9178696
BMC Res Notes. 2009 Jun 15;2:105
pubmed: 19527493
Hepatology. 2012 Feb;55(2):506-11
pubmed: 21953406
J Hepatol. 2009 Jun;50(6):1210-8
pubmed: 19395113
J Clin Invest. 2018 May 1;128(5):1903-1912
pubmed: 29461980
PLoS One. 2016 Jan 08;11(1):e0146086
pubmed: 26744892
Nat Rev Immunol. 2015 Apr;15(4):243-54
pubmed: 25743219
Hepatology. 2007 Aug;46(2):463-71
pubmed: 17634963
J Exp Med. 1994 Oct 1;180(4):1235-42
pubmed: 7931060
Cell Immunol. 2018 May;327:13-20
pubmed: 29551191
PLoS One. 2017 Oct 31;12(10):e0187325
pubmed: 29088299
Eur J Immunol. 1997 Feb;27(2):568-71
pubmed: 9045932
Genes Immun. 2016 Apr;17(3):187-92
pubmed: 26890333
Lancet. 2013 Oct 26;382(9902):1433-44
pubmed: 23768844
J Hepatol. 2013 Jan;58(1):141-7
pubmed: 22989569
Immunogenetics. 1989;30(3):200-7
pubmed: 2777338
PLoS One. 2018 Apr 12;13(4):e0195778
pubmed: 29649328
J Hepatol. 1999 Nov;31(5):929-38
pubmed: 10580593
Nat Rev Immunol. 2005 Mar;5(3):201-14
pubmed: 15719024
J Immunol. 1996 May 1;156(9):3098-101
pubmed: 8617928